111.43
1.85%
2.02
Handel nachbörslich:
111.43
Finanzdaten der Jazz Pharmaceuticals Plc-Aktie (JAZZ)
Gewinn- und Verlustrechnung
Vierteljährlich
*Alle Zahlen in Millionen
Enddatum des Zeitraums | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 |
Periodenlänge | 3 Monate | 3 Monate | 3 Monate | 3 Monate | 3 Monate |
Revenues |
10.87%
901.98
|
1,011.93 | 972.14 | 957.32 | 892.81 |
Operating Expenses
|
6.03%
835.78
|
889.44 | 799.75 | 799.68 | 766.76 |
Benefits Costs and Expenses |
4.93%
903.59
|
950.41 | 872.62 | 875.53 | 837.71 |
Costs And Expenses |
6.03%
835.78
|
889.44 | 799.75 | 799.68 | 766.76 |
Operating Income/Loss |
45.95%
66.21
|
122.50 | 172.39 | 157.64 | 126.06 |
Income/Loss Before Equity Method Investments |
102.60%
-1.602
|
61.53 | 99.52 | 81.78 | 55.10 |
Income/Loss From Equity Method Investments |
192.19%
-1.347
|
-0.461 | 0.126 | -1.669 | -1.005 |
Income/Loss From Continuing Operations Before Tax |
102.60%
-1.602
|
61.53 | 99.52 | 81.78 | 55.10 |
Income Tax Expense/Benefit, Deferred |
84.92%
-66.39
|
-35.90 | -78.92 | -79.33 | -66.06 |
Income Tax Expense/Benefit |
135.27%
11.67
|
-33.09 | -47.18 | -24.32 | -15.32 |
Income/Loss From Continuing Operations After Tax |
114.03%
-13.27
|
94.61 | 146.69 | 104.44 | 69.42 |
Net Income/Loss
|
115.53%
-14.62
|
94.15 | 146.82 | 104.44 | 69.42 |
Preferred Stock Dividends And Other Adjustments |
-
|
- | - | - | - |
Attributable To Noncontrolling Interest |
-
|
- | - | - | - |
Basic Average Shares |
26,049%
62.54
|
-0.241 | 63.11 | 63.99 | 63.49 |
Diluted Average Shares |
7,917%
62.54
|
-0.80 | 71.29 | 73.54 | 73.77 |
Basic Earnings Per Share |
115.33%
-0.23
|
1.50 | 2.33 | 1.63 | 1.09 |
Diluted Earnings Per Share |
116.08%
-0.23
|
1.43 | 2.14 | 1.52 | 1.04 |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic |
-
|
- | - | - | - |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):